SecBot SecBot
8-K ·Filed Nov 16, 2026

JAGX

Jaguar Health, Inc.
BEARISH
Impact 6/10
Horizonmonths Processed5d 21h ago SEC0001193125-26-462345
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The revenue decline reflects the structural shift to a cost-plus distribution model with no visibility into end-market sales. Monitor the ATM drawdown pace and any clinical milestones for crofelemer in MVID, as the NDA filing in mid-2027 is the primary value catalyst.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

JAGX drug pipeline →

Gelclair

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already FDA-approved and commercially launched in the U.S. as of October 2024.
Next catalyst
None dated

What to watchGelclair is already approved and launched, so the main thing to watch is whether Jaguar's commercial efforts gain traction in the oral mucositis market. The company has shifted strategic focus to rare-disease crofelemer programs (MVID NDA filing targeted mid-2027) and out-licensed its core Mytesi/Canalevia products to Future Pak in January 2026. Gelclair appears to be a smaller part of the portfolio now. The near-term binary catalyst for JAGX is the December 21, 2026 PDUFA for Canalevia (veterinary CID), not Gelclair.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.3864
T+0 close · Nov 16, 2026 · via day close
Latest settled
−1.68%
T+1 · $0.3799
Vs SPY
−0.67%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 16 $0.3864entry
  2. T+1 · 5d ago −1.68%α −0.67% · $0.3799
  3. T+4 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Jaguar Health reported Q3 2026 total revenue of $2.3M, down 24% YoY from $3.1M, driven by an 82% decline in product revenue to $0.55M after licensing U.S. commercial rights to Future Pak. Net loss narrowed 40% to $5.8M from $9.6M, and the company reduced debt by $10.1M via a stock-for-debt exchange with Streeterville. A planned NDA filing for crofelemer in MVID in mid-2027 provides a long-term catalyst, but the revenue decline and extreme dilution risk from a $75M ATM program (15x market cap) dominate the near-term outlook.

Key Financial Metrics

EPS
−$9.23
Revenue
$2.3M
est $0.00 · -24.0% YoY

Key Facts

  • Total revenue fell 24% YoY to $2.3M in Q3 2026 from $3.1M
  • Product revenue dropped 82% YoY to $0.55M after licensing Mytesi/Canalevia to Future Pak
  • Net loss narrowed 40% to $5.8M from $9.6M
  • Debt reduced by $10.1M via stock-for-debt exchange with Streeterville
  • Planned NDA filing for crofelemer in MVID in mid-2027
  • $75M ATM program filed 7 days ago represents 15x current $5M market cap

Financial Impact

Revenue decline of $0.74M (24% YoY); net loss improvement of $3.8M (40% narrowing); debt reduction of $10.1M

revenueproduct revenuenet lossdebt

Segment Breakdown

SegmentRevenueGrowth
License and grant revenue$1.8M+4166.7%
Product revenue$551.0K-81.9%

Risk Factors

  • Extreme dilution risk from $75M ATM program at $5M market cap
  • No visibility into Future Pak's Mytesi sales as they are privately held
  • Pre-revenue biotech with ongoing operating losses and reliance on equity/debt financing
  • Planned NDA filing in mid-2027 is over 6 months away with regulatory uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-462345
Document: d192965d8k.htm0001193125-26-462345
Document: 0001193125-26-462345-index-headers.html0001193125-26-462345
Document: 0001193125-26-462345-index.html0001193125-26-462345
Document: 0001193125-26-462345.txt0001193125-26-462345
8-K Data (Synthetic)0001193125-26-462345

Track record

33 reports on JAGX

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +97.54% at T+1 after the Apr 27, 2026 report. 20 of 22 went positive at some point.

Filters
  1. Nov 20, 20261d ago 8-K Bearish 5/10 Entry $0.2877 Now $0.2270 +21.10% settles Feb 19
  2. Nov 16, 20265d ago 8-K Bearish 6/10 Viewing Entry $0.3864 Now $0.2270 +41.25% settles Feb 12
  3. Nov 9, 202612d ago 424B5 Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
  4. Nov 6, 202615d ago 8-K Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
  5. Nov 6, 202616d ago EFFECT Bearish 5/10 Entry $0.4043 Now $0.2270 +43.85% settles Feb 4
  6. Nov 3, 202618d ago S-3/A Bearish 5/10 Entry $0.5575 Now $0.2270 +59.28% settles Feb 1
  7. Nov 3, 202618d ago 8-K Neutral 2/10 Entry $0.5575 Now $0.2270 −59.28% settles Feb 1
  8. Oct 29, 202623d ago DEFA14A Bearish 6/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 27
  9. Oct 28, 202624d ago 8-K Neutral 2/10 Entry $2.04 Now $0.2270 −88.87% settles Jan 27
  10. Oct 22, 20264w ago S-3 Bearish 5/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 21
Showing 10 of 33

US Market Status

Market Closed · Opens Mon (26h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026